



PEP-Therapy to Present Clinical Phase Ia Data on PEP-010 in Solid Tumors at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Paris (France), October 5, 2023 – PEP-Therapy, a clinical-stage biotechnology company developing first-in-class peptides as targeted therapies in oncology, today announced that it will present the results from the dose escalation part of the CLEVer-PEptide Phase Ia/b study on its lead drug candidate, PEP-010, in patients with recurrent and/or metastatic solid cancer, at the upcoming AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, taking place October 11-15, 2023 in Boston, MA.

Details for the poster presentations are as follows:

Title: A first-in-human Phase 1a/b of PEP-010, a proapoptotic bifunctional peptide, administered as single agent and in combination with paclitaxel in patients with recurrent and/or metastatic solid cancer: results from the dose escalation study

Presenter: Christophe Le Tourneau, Department of Drug Development and Innovation, Institut Curie, Paris, France

Poster number: B046

Session: Poster Session B

Session date and time: Friday, October 13 | 12:30 pm - 4:00 pm ET

Session location: Level 2, Exhibit Hall D

About PEP-Therapy

PEP-Therapy is a Paris-based clinical-stage biotechnology company developing first-in-class peptides as targeted therapies in oncology. PEP-010, leading drug candidate, is a pro-apoptotic agent currently evaluated in a Phase Ia/b clinical trial. The company also develops a pipeline of peptide-based products in oncology.

PEP-Therapy, which was founded in 2014 and builds on research from Sorbonne University and Institut Curie, is backed by international investors: Seventure Partners (Quadrivium 1 Seed Fund), Anaxago, i&i Prague, Italian Angels for Growth (IAG), Doorway, Magna Capital Partners (MCP), Business Angels des Grandes Ecoles (BADGE), and Jérôme Majoie (former Managing Director of Laboratoires Fournier affiliates (USA, UK, Sweden, Japan), CEO of La Fondation Fournier-Majoie).

For more information, please visit www.pep-therapy.com.

About PEP-010

PEP-010 is a first-in-class bifunctional peptide that penetrates cells and specifically disrupts the interaction between Caspase-9 and PP2A, two proteins involved in the apoptotic cascade, leading to Caspase-9-dependent apoptosis in cancer cells. PEP-010 is currently evaluated in a Phase Ia/b clinical trial.

About CLEVer-Peptide trial

CLEVer-PEptide is a Phase Ia/b, open-label, non controlled, multicenter clinical study (NCT 04733027). It is a first-in-human clinical study evaluating PEP-010 as a single agent and in combination with paclitaxel, in patients with recurrent and/or metastatic solid tumors. It is a dose escalation trial (Phase Ia) with an expansion phase (Phase Ib). It is conducted in partnership with two leading European cancer centers, Institut Curie and Gustave Roussy, and at François Baclesse center. CLEVer-Peptide is led by Professor Christophe Le Tourneau, Medical Oncologist at Institut Curie and Head of the Department of Drug Development and Innovation (D3i), and Principal Investigator of the trial.

Contact

PEP-Therapy: Antoine Prestat, CEO & co-founder

hello.pep@pep-therapy.com

+33 1 83 97 13 35